Stockscreener 앱 받기
1.84
1.10%
0.02
시장 영업 전:
1.91
0.07
+3.80%
전일 마감가:
$1.82
열려 있는:
$1.82
하루 거래량:
3.20M
Relative Volume:
1.23
시가총액:
$385.80M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.8679
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-4.17%
1개월 성능:
-1.60%
6개월 성능:
-34.98%
1년 성능:
-40.45%
1일 변동 폭
$1.78
$1.905
1주일 범위
$1.78
$2.10
52주 변동 폭
$1.78
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.84 | 385.80M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Zacks Research Issues Pessimistic Estimate for ALLO Earnings - Defense World
What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - MSN
Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada
Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com
Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector Decline - GuruFocus.com
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire
Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com
Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha
Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat
Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart
Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):